Huntington National Bank’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $222K | Hold |
701
| – | – | ﹤0.01% | 883 |
|
|
2026
Q1 | $140K | Hold |
701
| – | – | ﹤0.01% | 968 |
|
|
2025
Q4 | $133K | Buy |
701
+697
| +17,425% | +$134K | ﹤0.01% | 884 |
|
|
2025
Q3 | $708 | Hold |
4
| – | – | ﹤0.01% | 2340 |
|
|
2025
Q2 | $455 | Hold |
4
| – | – | ﹤0.01% | 2458 |
|
|
2025
Q1 | $420 | Sell |
4
-38
| -90% | -$4.3K | ﹤0.01% | 2491 |
|
|
2024
Q4 | $4.5K | Hold |
42
| – | – | ﹤0.01% | 2033 |
|
|
2024
Q3 | $4.2K | Hold |
42
| – | – | ﹤0.01% | 2048 |
|
|
2024
Q2 | $3.54K | Buy |
42
+3
| +8% | +$239 | ﹤0.01% | 2006 |
|
|
2024
Q1 | $2.85K | Hold |
39
| – | – | ﹤0.01% | 2058 |
|
|
2023
Q4 | $2.79K | Buy |
39
+38
| +3,800% | +$2.24K | ﹤0.01% | 2012 |
|
|
2023
Q3 | $60 | Sell |
1
-12
| -92% | -$790 | ﹤0.01% | 2568 |
|
|
2023
Q2 | $937 | Buy |
13
+12
| +1,200% | +$900 | ﹤0.01% | 2184 |
|
|
2023
Q1 | $74 | Hold |
1
| – | – | ﹤0.01% | 2292 |
|
|
2022
Q4 | $67 | Sell |
1
-1
| -50% | -$65 | ﹤0.01% | 2198 |
|
|
2022
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 2222 |
|
|
2022
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 2240 |
|
|
2022
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 2207 |
|
|
2021
Q4 | $0 | Buy |
+2
| New | +$185 | ﹤0.01% | 2162 |
|
|
2020
Q4 | – | Sell |
-391
| Closed | -$23K | – | 1674 |
|
|
2020
Q3 | $23K | Buy |
391
+8
| +2% | +$546 | ﹤0.01% | 1004 |
|
|
2020
Q2 | $27K | Buy |
383
+151
| +65% | +$9.57K | ﹤0.01% | 934 |
|
|
2020
Q1 | $11K | Sell |
232
-106
| -31% | -$6.01K | ﹤0.01% | 1173 |
|
|
2019
Q4 | $22K | Sell |
338
-48
| -12% | -$3.21K | ﹤0.01% | 1223 |
|
|
2019
Q3 | $24K | Sell |
386
-74
| -16% | -$4.65K | ﹤0.01% | 1067 |
|
|
2019
Q2 | $33K | Buy |
460
+53
| +13% | +$3.9K | ﹤0.01% | 981 |
|
|
2019
Q1 | $32K | Buy |
407
+83
| +26% | +$6.29K | ﹤0.01% | 985 |
|
|
2018
Q4 | $27K | Buy |
324
+10
| +3% | +$1.07K | ﹤0.01% | 1048 |
|
|
2018
Q3 | $54K | Sell |
314
-24
| -7% | -$3.62K | ﹤0.01% | 931 |
|
|
2018
Q2 | $44K | Sell |
338
-104
| -24% | -$11.6K | ﹤0.01% | 986 |
|
|
2018
Q1 | $46K | Sell |
442
-172
| -28% | -$17K | ﹤0.01% | 979 |
|
|
2017
Q4 | $52K | Hold |
614
| – | – | ﹤0.01% | 964 |
|
|
2017
Q3 | $52K | Sell |
614
-29
| -5% | -$2.3K | ﹤0.01% | 964 |
|
|
2017
Q2 | $49K | Buy |
643
+167
| +35% | +$11.7K | ﹤0.01% | 951 |
|
|
2017
Q1 | $31K | Buy |
476
+5
| +1% | +$329 | ﹤0.01% | 997 |
|
|
2016
Q4 | $30K | Sell |
471
-10
| -2% | -$631 | ﹤0.01% | 1031 |
|
|
2016
Q3 | $31K | Buy |
481
+220
| +84% | +$16.2K | ﹤0.01% | 1033 |
|
|
2016
Q2 | $19K | Buy |
+261
| New | +$19.4K | ﹤0.01% | 1143 |
|
|
2016
Q1 | – | Sell |
-173
| Closed | -$12K | – | 1775 |
|
|
2015
Q4 | $12K | Buy |
+173
| New | +$10.7K | ﹤0.01% | 1336 |
|
Other funds holding LGND
JT
CAM
Huntington National Bank's LGND Position: Q2 2026 in Review
Huntington National Bank held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 701 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #883.
Huntington National Bank first reported a position in LGND in Q4 2015 and has held it in 38 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Huntington National Bank held 701 shares of Ligand Pharmaceuticals worth $222K as of Q2 2026.
- Huntington National Bank left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
- Ligand Pharmaceuticals made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #883 holding.
- Huntington National Bank first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 38 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.